Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry

British Journal of Haematology

Volumn 170, Issue 3, 2015, Pages 372-383

  de Swart, Louise ^a   Smith, Alex ^b   Johnston, Thomas W ^b   Haase, Detlef ^c   Droste, Jackie ^a   Fenaux, Pierre ^d   Symeonidis, Argiris ^e   Sanz, Guillermo ^f   Hellström Lindberg, Eva ^g   Cermák, Jaroslav ^h   Germing, Ulrich ⁱ   Stauder, Reinhard ^j   Georgescu, Otilia ^k   MacKenzie, Marius ^a   Malcovati, Luca ^l   Holm, Mette S ^m   Almeida, Antonio M ⁿ   Mądry, Krzysztof ^o   Slama, Borhane ^p   Guerci Bresler, Agnes ^q   Sanhes, Laurence ^r   Beyne Rauzy, Odile ^s   Luño, Elisa ^t   Bowen, David ^u   de Witte, Theo ^v   more..

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF YORK   (United Kingdom)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIVERSITY OF PATRAS   (Greece)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g KAROLINSKA INSTITUTE   (Sweden)

^h INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

ⁱ UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^j INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^k FUNDENI CLINICAL INSTITUTE   (Romania)

^l UNIVERSITY OF PAVIA   (Italy)

^m AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁿ INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^o MEDICAL UNIVERSITY OF WARSAW   (Poland)

^p CENTRE HOSPITALIER D AVIGNON   (France)

^q UNIVERSITY HOSPITAL OF NANCY   (France)

^r Centre Hospitalier de Perpignan   (France)

^s CHU PURPAN   (France)

^t Servicio de Salud del Principado de Asturias   (Spain)

^u LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^v RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

co morbidity score; International Prognostic Scoring System; lower risk myelodysplastic syndromes; quality of life score; revised International Prognostic Scoring System

Indexed keywords

HEMOPOIETIC GROWTH FACTOR;

ADULT; AGED; ARTICLE; CHELATION THERAPY; DISEASE COURSE; ERYTHROCYTE TRANSFUSION; FEMALE; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; IRON CHELATION; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PREDICTION; PRIORITY JOURNAL; SURVIVAL RATE; VALIDATION STUDY; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROSPECTIVE STUDY; REGISTER; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS;

EID: 84942121801     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13450     Document Type: Article

References (39)

1. Akaike, H. (1974) New look at statistical-model identification. Ieee Transactions on Automatic Control, Ac19, 716–723.
2. Aul, C., Gattermann, N. & Schneider, W. (1992) Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. British Journal of Haematology, 82, 358–367.
3. Aul, C., Bowen, D.T. & Yoshida, Y. (1998) Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica, 83, 71–86.
4. Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R.L., Neuberg, D. & Ebert, B.L. (2011) Clinical effect of point mutations in myelodysplastic syndromes. New England Journal of Medicine, 364, 2496–2506.
5. Bennett, J.M. (2000) World Health Organization classification of the acute leukemias and myelodysplastic syndrome. International Journal of Hematology, 72, 131–133.
6. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189–199.
7. Cazzola, M. & Malcovati, L. (2005) Myelodysplastic syndromes–coping with ineffective hematopoiesis. New England Journal of Medicine, 352, 536–538.
8. Della Porta, M.G., Malcovati, L., Strupp, C., Ambaglio, I., Kuendgen, A., Zipperer, E., Travaglino, E., Invernizzi, R., Pascutto, C., Lazzarino, M., Germing, U. & Cazzola, M. (2011) Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica, 96, 441–449.
9. Fenaux, P. & Ades, L. (2013) How we treat lower-risk myelodysplastic syndromes. Blood, 121, 4280–4286.
10. Germing, U., Aul, C., Niemeyer, C.M., Haas, R. & Bennett, J.M. (2008) Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Annals of Hematology, 87, 691–699.
11. Goldberg, S.L., Chen, E., Corral, M., Guo, A., Mody-Patel, N., Pecora, A.L. & Laouri, M. (2010) Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. Journal of Clinical Oncology, 28, 2847–2852.
12. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079–2088.
13. Greenberg, P.L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Sole, F., Bennett, J.M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., Cermak, J., Fonatsch, C., Le Beau, M.M., Slovak, M.L., Krieger, O., Luebbert, M., Maciejewski, J., Magalhaes, S.M., Miyazaki, Y., Pfeilstocker, M., Sekeres, M., Sperr, W.R., Stauder, R., Tauro, S., Valent, P., Vallespi, T., van de Loosdrecht, A.A., Germing, U. & Haase, D. (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood, 120, 2454–2465.
14. Hamaker, M.E., Stauder, R. & van Munster, B.C. (2014) On-going clinical trials for elderly patients with a hematological malignancy: are we addressing the right end points? Annals of Oncology, 25, 675–681.
15. Harrell, F.E. Jr, Lee, K.L. & Mark, D.B. (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistics in Medicine, 15, 361–387.
16. Hellstrom-Lindberg, E., Gulbrandsen, N., Lindberg, G., Ahlgren, T., Dahl, I.M., Dybedal, I., Grimfors, G., Hesse-Sundin, E., Hjorth, M., Kanter-Lewensohn, L., Linder, O., Luthman, M., Lofvenberg, E., Oberg, G., Porwit-MacDonald, A., Radlund, A., Samuelsson, J., Tangen, J.M., Winquist, I., Wisloff, F. & Scandinavian, M.D.S.G. (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology, 120, 1037–1046.
17. Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G. & Badia, X. (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20, 1727–1736.
18. Kelaidi, C., Stamatoullas, A., Beyne-Rauzy, O., Raffoux, E., Quesnel, B., Guerci, A., Dreyfus, F., Brechignac, S., Berthou, C., Prebet, T., Hicheri, Y., Hacini, M., Delaunay, J., Gourin, M.P., Camo, J.M., Zerazhi, H., Taksin, A.L., Legros, L., Choufi, B. & Fenaux, P. & Groupe Francophone des Myelodysplasies. (2010) Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. Haematologica, 95, 892–899.
19. Kuendgen, A., Strupp, C., Aivado, M., Hildebrandt, B., Haas, R., Gattermann, N. & Germing, U. (2006) Myelodysplastic syndromes in patients younger than age 50. Journal of Clinical Oncology, 24, 5358–5365.
20. van de Loosdrecht, A.A., Ireland, R., Kern, W., Della Porta, M.G., Alhan, C., Balleisen, J.S., Bettelheim, P., Bowen, D.T., Burbury, K., Eidenschink, L., Cazzola, M., Chu, S.S., Cullen, M., Cutler, J.A., Drager, A.M., Feuillard, J., Fenaux, P., Font, P., Germing, U., Haase, D., Hellstrom-Lindberg, E., Johansson, U., Kordasti, S., Loken, M.R., Malcovati, L., te Marvelde, J.G., Matarraz, S., Milne, T., Moshaver, B., Mufti, G.J., Nikolova, V., Ogata, K., Oelschlaegel, U., Orfao, A., Ossenkoppele, G.J., Porwit, A., Platzbecker, U., Preijers, F., Psarra, K., Richards, S.J., Subira, D., Seymour, J.F., Tindell, V., Vallespi, T., Valent, P., van der Velden, V.H., Wells, D.A., de Witte, T.M., Zettl, F., Bene, M.C. & Westers, T.M. (2013) Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leukaemia & Lymphoma, 54, 472–475.
21. Ma, X. (2012) Epidemiology of myelodysplastic syndromes. American Journal of Medicine, 125, S2–S5.
22. Malcovati, L., Hellstrom-Lindberg, E., Bowen, D., Ades, L., Cermak, J., Del Canizo, C., Della Porta, M.G., Fenaux, P., Gattermann, N., Germing, U., Jansen, J.H., Mittelman, M., Mufti, G., Platzbecker, U., Sanz, G.F., Selleslag, D., Skov-Holm, M., Stauder, R., Symeonidis, A., van de Loosdrecht, A.A., de Witte, T., Cazzola, M. & European Leukemia, N. (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood, 122, 2943–2964.
23. Neukirchen, J., Lauseker, M., Blum, S., Giagounidis, A., Lubbert, M., Martino, S., Siragusa, S., Schlenk, R.F., Platzbecker, U., Hofmann, W.K., Gotze, K., Palumbo, G.A., Magrin, S., Kundgen, A., Aul, C., Hildebrandt, B., Hasford, J., Kobbe, G., Haas, R. & Germing, U. (2014) Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. Leukemia Research, 38, 57–64.
24. Nosslinger, T., Tuchler, H., Germing, U., Sperr, W.R., Krieger, O., Haase, D., Lubbert, M., Stauder, R., Giagounidis, A., Valent, P. & Pfeilstocker, M. (2010) Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Annals of Oncology, 21, 120–125.
25. Park, S., Grabar, S., Kelaidi, C., Beyne-Rauzy, O., Picard, F., Bardet, V., Coiteux, V., Leroux, G., Lepelley, P., Daniel, M.T., Cheze, S., Mahe, B., Ferrant, A., Ravoet, C., Escoffre-Barbe, M., Ades, L., Vey, N., Aljassem, L., Stamatoullas, A., Mannone, L., Dombret, H., Bourgeois, K., Greenberg, P., Fenaux, P. & Dreyfus, F. & G.F.M. group (2008) Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood, 111, 574–582.
26. Phekoo, K.J., Richards, M.A., Moller, H. & Schey, S.A. & South Thames Haematology Specialist Committee (2006) The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica, 91, 1400–1404.
27. Rollison, D.E., Howlader, N., Smith, M.T., Strom, S.S., Merritt, W.D., Ries, L.A., Edwards, B.K. & List, A.F. (2008) Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood, 112, 45–52.
28. Schanz, J., Tuchler, H., Sole, F., Mallo, M., Luno, E., Cervera, J., Granada, I., Hildebrandt, B., Slovak, M.L., Ohyashiki, K., Steidl, C., Fonatsch, C., Pfeilstocker, M., Nosslinger, T., Valent, P., Giagounidis, A., Aul, C., Lubbert, M., Stauder, R., Krieger, O., Garcia-Manero, G., Faderl, S., Pierce, S., Le Beau, M.M., Bennett, J.M., Greenberg, P., Germing, U. & Haase, D. (2012) New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. Journal of Clinical Oncology, 30, 820–829.
29. Sekeres, M.A. (2010) The epidemiology of myelodysplastic syndromes. Hematology/Oncology Clinics of North America, 24, 287–294.
30. Sekeres, M.A. (2011) Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. Journal of the National Comprehensive Cancer Network, 9, 57–63.
31. Smith, A., Roman, E., Howell, D., Jones, R., Patmore, R. & Jack, A. & Haematological Malignancy Research Network (2010) The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. British Journal of Haematology, 148, 739–753.
32. van Spronsen, M.F., Ossenkoppele, G.J., Holman, R. & van de Loosdrecht, A.A. (2014) Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index. European Journal of Cancer, 50, 3198–3205.
33. Stauder, R. (2012) The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients. Annals of Hematology, 91, 1333–1343.
34. Vardiman, J.W., Thiele, J., Arber, D.A., Brunning, R.D., Borowitz, M.J., Porwit, A., Harris, N.L., Le Beau, M.M., Hellstrom-Lindberg, E., Tefferi, A. & Bloomfield, C.D. (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937–951.
35. Visser, O., Trama, A., Maynadie, M., Stiller, C., Marcos-Gragera, R., De Angelis, R., Mallone, S., Tereanu, C., Allemani, C., Ricardi, U. & Schouten, H.C. & RARECARE working Group (2012) Incidence, survival and prevalence of myeloid malignancies in Europe. European Journal of Cancer, 48, 3257–3266.
36. Voso, M.T., Fenu, S., Latagliata, R., Buccisano, F., Piciocchi, A., Aloe-Spiriti, M.A., Breccia, M., Criscuolo, M., Andriani, A., Mancini, S., Niscola, P., Naso, V., Nobile, C., Piccioni, A.L., D'Andrea, M., D'Addosio, A., Leone, G. & Venditti, A. (2013) Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. Journal of Clinical Oncology, 31, 2671–2677.
37. Wildiers, H., Mauer, M., Pallis, A., Hurria, A., Mohile, S.G., Luciani, A., Curigliano, G., Extermann, M., Lichtman, S.M., Ballman, K., Cohen, H.J., Muss, H. & Wedding, U. (2013) End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer–Alliance for Clinical Trials in Oncology-International Society Of Geriatric Oncology position article. Journal of Clinical Oncology, 31, 3711–3718.
38. Zeidan, A.M., Lee, J.W., Prebet, T., Greenberg, P., Sun, Z., Juckett, M., Smith, M.R., Paietta, E., Gabrilove, J., Erba, H.P., Tallman, M.S. & Gore, S.D., Eastern Cooperative Oncology Group & North American Leukemia intergroup. (2014) Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. British Journal of Haematology, 166, 352–359.
39. Zipperer, E., Tanha, N., Strupp, C., Kundgen, A., Nachtkamp, K., Neukirchen, J., Hildebrandt, B., Haas, R., Gattermann, N. & Germing, U. (2014) The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system. Haematologica, 99, e31–e32.